$PRAX News

Goldman Sachs Maintains Buy on Praxis Precision Medicine, Raises Price Target to $575

Is Praxis (PRAX) Trading Bigger Losses for Long-Run CNS Ambition With Its Cash War Chest?

Praxis: Commercial Launch Could Smash Expectations (Video)

RBC Capital Maintains Outperform on Praxis Precision Medicine, Raises Price Target to $462

Praxis Precision Medicines, Inc. Q2 2026 Earnings Call Summary

Wells Fargo Maintains Equal-Weight on Praxis Precision Medicine, Raises Price Target to $362

Praxis Precision Medicines, Inc. (PRAX) Q2 2026 Earnings Call Transcript

Praxis Precision Medicines Q2 Earnings Call Highlights

Praxis Precision Medicines Inc (PRAX) (Q2 2026) Earnings Call Highlights: FDA Approvals on ...

Needham Maintains Buy on Praxis Precision Medicine, Raises Price Target to $582

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Praxis Precision Medicine Q2 EPS $(2.87) Beats $(3.65) Estimate

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

BTIG Reiterates Buy on Praxis Precision Medicine, Maintains $810 Price Target

Praxis Precision Medicines: Priced For Half Of What I Think It's Worth

Praxis Precision Medicines (PRAX) Enters Into Licensing and Research Collaboration With Remagine Labs

Goldman Sachs Initiates Coverage On Praxis Precision Medicine with Buy Rating, Announces Price Target of $447

Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor

Praxis Precision Medicines And Remagine Labs Announce Research Collaboration And License Agreement To Develop Iontophoretic Transdermal Patch For Delivery Of Ulixacaltamide For Essential Tremor